| COHERUS ONCOLOGY DL-,0001 |
| USA |
| Gesundheit |
| US19249H1032 / A12ETZ |
| 8C5 (Frankfurt) / CHRS (NASDAQ) |
| FRA:8C5, ETR:8C5, 8C5:GR, NASDAQ:CHRS |
| - |
| https://www.coherus.com/ |
|
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used i..
>Volltext.. |
| 117.91 Mio. EUR |
| 72.79 Mio. EUR |
| 45.72 Mio. EUR |
| -137.33 Mio. EUR |
| -117.27 Mio. EUR |
| -0.92 EUR |
| 48.63 Mio. EUR |
| 74.44 Mio. EUR |
| -166.99 Mio. EUR |
| 1.39 |
| -63.2% |
| 15.43% |
| - |
| - |
| - |
| - |
| COHERUS |
| 10.11.26 |
|